Stavzor approved for bipolar disorder, seizure, and migraine treatment

The FDA has approved Stavzor (valproic acid delayed-release capsules, from Noven) for the treatment of manic episodes in bipolar disorder, complex partial seizures, and migraine prophylaxis. Stavzor’s enteric soft gelatin capsule formulation is intended to improve compliance by being easier to swallow and reducing gastric reflux and gastric irritability.

Stavzor is expected to be available in the second half of August 2008 in 125mg, 250mg and 500mg dosage strengths.

For more information call (305) 253-5099 or visit